# Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Study · id `cardio:ct-nct01305148` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01305148](<https://clinicaltrials.gov/study/NCT01305148>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01305148

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 3800 participants.

## Technical summary

Registry record NCT01305148. Randomized; quadruple masking; primary purpose prevention. Start 2011-08 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 3800 participants (planned count; ClinicalTrials.gov record NCT01305148, source copy `cardio:ctgov-nct01305148-2015-08-31`, retrieved 2026-10-26)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01305148, source copy `cardio:ctgov-nct01305148-2015-08-31`, retrieved 2026-10-26)
- Primary completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01305148, source copy `cardio:ctgov-nct01305148-2015-08-31`, retrieved 2026-10-26)
- Completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01305148, source copy `cardio:ctgov-nct01305148-2015-08-31`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01305148, source copy `cardio:ctgov-nct01305148-2015-08-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01305148-2015-08-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
- Acronym: WARFARIN
- Condition: Anti-coagulation Therapy
- Condition: DVT
- Condition: Pulmonary Embolism
- Condition: Joint Surgery Multiple
- Condition: Atrial Fibrillation
- Condition: Prosthetic Replacement of Mitral Valve
- Intervention (Device): Warfarin GenoSTAT Test
- Lead sponsor: Iverson Genetic Diagnostics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)

## Provenance

Content hash: a4d2779c5430c3b7bc5063ec30c7c02b079ade90c4b2b561ec8d1282c0bea929
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
